Page contentsPage contents Key facts Decision Related medicine information Key facts Invented name Mektovi Active substance binimetinib Therapeutic area Oncology Decision number P/0349/2023 PIP number EMEA-001454-PIP06-23 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of lung cancer Route(s) of administration All routes of administration Contact for public enquiries Pierre Fabre Médicament E-mail: medical_information@pierre-fabre.comTel. +33 800326326 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 08/09/2023 Compliance check done No Decision P/0349/2023 : EMA decision of 8 September 2023 on the granting of a product specific waiver for binimetinib (Mektovi), (EMEA-001454-PIP06-23)Reference Number: EMA/380483/2023 English (EN) (189.85 KB - PDF)First published: 19/09/2024 View Related medicine information Mektovi Share this page